Navigation Links
Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
Date:4/29/2008

NEWPORT NEWS, Va., April 29 /PRNewswire/ -- Recently published data in The American Journal of Surgery by a group of surgeons from Legacy Good Samaritan Hospital in Portland, Oregon, demonstrates the value of using Breast-Specific Gamma Imaging (BSGI) for the clinical management of breast cancer patients.

The breast center's first year's experience with BSGI showed the upside of using physiological data obtained from the functional imaging of BSGI over imaging techniques that convey mostly anatomical data -- such as mammography, ultrasound and MRI. Specifically, the results of the study showed that BSGI:

-- Changed patient management in 14% of the cases,

-- Detected cancer in 2% of patients with no mammographic findings,

-- Detected additional cancers in 6% of patients with known breast

disease,

-- Correctly ruled out the need for biopsy in 86% of patients with

suspicious mammograms,

-- Had a false positive rate of only 6%, as compared to 78% in a

comparable MRI study.

The authors noted that breast density can cause the effectiveness of mammography to greatly decrease, so other imaging tests are needed to help address this group of high-risk patients. BSGI is not affected by breast density and has exhibited not only high sensitivity for detecting cancer, but also a strong ability to help rule it out.

In the retrospective study, performed by Dr. Nathalie Johnson and colleagues, BSGI was determined to play an important role in their management of patients with complex breast tissue and newly diagnosed cancers. In addition, Legacy Good Samaritan Hospital noted that cost of BSGI was one-third that of MRI for their facility.

Dr. David Maccabee, a surgeon practicing in Hood River, Oregon, stated, this data was clinically relevant and may change the way surgeons practice surgery in the future.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
3. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
4. On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
5. Hospital to Hold MRSA Briefing for Media and Community Leaders
6. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
10. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
11. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
(Date:4/28/2016)... , April 28, 2016   Acsis , ... announced that leading IT market research and advisory firm ... in the IDC MarketScape: Worldwide Pharmaceutical Track and Trace ... The report provides an assessment of the capabilities and ... and trace software market. Logo - ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick ... in Rio. Under the care of Maximized Living doctors at the London Olympics ... showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio to ...
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie ... best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live ... thereafter . Dr. Bernie Siegel, author of a plethora of essential books-to-read ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
Breaking Medicine News(10 mins):